EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Safety of Pharmaceutical Nanosuspensions in Drug Delivery: Evidence, Knowledge Gaps, and Safety-By-Design Strategies

Yingying Ma iD, Liuying Wang, Yancai Wang

Molecular Pharmaceutics · 03.08.2026 · 23 (8) · 4003-4024

DOI: 10.1021/acs.molpharmaceut.6c00558 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 18.07.2026. Verfasst von Yingying Ma und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Qilu Normal University, Jinan250200, China. Hauptthemen laut MEDLINE: Nanoparticles, Drug Delivery Systems. Die Arbeit nennt 126 Literaturangaben. Gefördert von: Major Scientific and Technological Innovation Project of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poor aqueous solubility remains a major barrier to small-molecule drug development. Pharmaceutical nanosuspensions, composed mainly of drug nanocrystals stabilized by small amounts of excipients, can improve dissolution and have been translated into several oral products and long-acting injectables. However, their simple compositions do not make them biologically inert. Nanosizing changes the surface area, dissolution, interfacial properties, aggregation, and interactions with biological fluids, thereby affecting local and systemic safety. This review examines nanosuspension safety from a product-level perspective. It focuses on formulation states generated during storage, handling, administration, and biological exposure, with attention to particle-size distribution, large-particle tails, stabilizer coverage and free excipient, crystal form, dissolution behavior, redispersibility, and in-use stability. These attributes are linked to blood compatibility, complement activation, immune responses, route-specific toxicity, biodistribution, macrophage-associated retention, depot persistence, clinical experience, and regulatory translation. Current evidence supports nanosuspensions under well-controlled conditions, especially for oral nanocrystal products and selected long-acting injectables. Key uncertainties remain for repeated intravenous use, chronic pulmonary exposure, particle-specific biodistribution, depot reversibility, long-term tissue exposure, and vulnerable populations. Safety assessment should, therefore, connect critical quality attributes with route-relevant exposure and biological responses, providing a basis for safety by design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesDrug Delivery SystemsHumansSuspensionsAnimalsSolubilityParticle SizeExcipientsAdministration, OralChemistry, PharmaceuticalDrug CompoundingTissue DistributionDrug Stability

Stichwörter der Autor:innen

clinical translationdrug nanocrystalshemocompatibilityimmunogenicitynanosuspensionsnanotoxicologysafety-by-design

Substanzen

SuspensionsExcipients

Autor:innen und Institutionen

  • School of Chemistry and Chemical Engineering, Qilu Normal University, Jinan250200, China.
  • Department of Pharmacy, Air Force Medical Center, PLA, Air Force Medical University, Beijing100142, China.
  • School of Chemistry and Chemical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan250353, China.

ORCID-Profile: Yingying Ma

Förderung

  • Major Scientific and Technological Innovation Project of Shandong Province

Zitieren

APA

Ma, Y., Wang, L., & Wang, Y. (2026). Safety of Pharmaceutical Nanosuspensions in Drug Delivery: Evidence, Knowledge Gaps, and Safety-By-Design Strategies. Molecular Pharmaceutics, 23(8), 4003-4024. https://doi.org/10.1021/acs.molpharmaceut.6c00558

Vancouver

Ma Y, Wang L, Wang Y. Safety of Pharmaceutical Nanosuspensions in Drug Delivery: Evidence, Knowledge Gaps, and Safety-By-Design Strategies. Molecular Pharmaceutics. 2026;23(8):4003-4024. doi:10.1021/acs.molpharmaceut.6c00558

BibTeX
@article{Ma2026,
  author = {Ma, Yingying and Wang, Liuying and Wang, Yancai},
  title = {Safety of Pharmaceutical Nanosuspensions in Drug Delivery: Evidence, Knowledge Gaps, and Safety-By-Design Strategies},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {8},
  pages = {4003--4024},
  doi = {10.1021/acs.molpharmaceut.6c00558}
}
Kostenlos starten →